BriaCell Therapeutics Corp. (BCT.TO)
4.89
-0.01
(-0.20%)
CAD |
TSX |
Nov 13, 16:00
BriaCell Therapeutics Enterprise Value : 12.59M for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 12.59M |
| November 12, 2026 | 12.67M |
| November 11, 2026 | 14.24M |
| November 10, 2026 | 15.29M |
| November 09, 2026 | 15.29M |
| November 06, 2026 | 18.51M |
| November 05, 2026 | 10.15M |
| November 04, 2026 | 8.754M |
| November 03, 2026 | 6.577M |
| November 02, 2026 | 7.361M |
| October 30, 2026 | 7.448M |
| October 29, 2026 | 10.50M |
| October 28, 2026 | 12.32M |
| October 27, 2026 | 13.63M |
| October 26, 2026 | 12.41M |
| October 23, 2026 | 11.72M |
| October 22, 2026 | 12.15M |
| October 21, 2026 | 14.24M |
| October 20, 2026 | 12.32M |
| October 19, 2026 | 11.89M |
| October 16, 2026 | 12.50M |
| October 15, 2026 | 16.68M |
| October 14, 2026 | 15.72M |
| October 13, 2026 | 16.24M |
| October 09, 2026 | 18.86M |
| Date | Value |
|---|---|
| October 08, 2026 | 18.42M |
| October 07, 2026 | 19.55M |
| October 06, 2026 | 19.64M |
| October 05, 2026 | 21.64M |
| October 02, 2026 | 20.07M |
| October 01, 2026 | 21.21M |
| September 30, 2026 | 23.12M |
| September 29, 2026 | 20.51M |
| September 28, 2026 | 19.90M |
| September 25, 2026 | 22.60M |
| September 24, 2026 | 22.43M |
| September 23, 2026 | 19.29M |
| September 22, 2026 | 19.99M |
| September 21, 2026 | 20.51M |
| September 18, 2026 | 21.47M |
| September 17, 2026 | 21.56M |
| September 16, 2026 | 13.37M |
| September 15, 2026 | 12.85M |
| September 14, 2026 | 13.37M |
| September 11, 2026 | 13.89M |
| September 10, 2026 | 13.46M |
| September 09, 2026 | 13.98M |
| September 08, 2026 | 12.24M |
| September 04, 2026 | 12.93M |
| September 03, 2026 | 12.41M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Kane Biotech, Inc. | 7.260M |
| Quest PharmaTech, Inc. | -- |
| Vaxil Bio Ltd. | -0.0258M |
| Waverley Pharma, Inc. | 4.639M |
| Goldcoast Resource Corp. | 0.7689M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -17.47M |
| Total Expenses (Quarterly) | 17.20M |
| EPS Diluted (Quarterly) | -1.976 |
| Earnings Yield | -264.7% |
| Normalized Earnings Yield | -267.12 |